284 related articles for article (PubMed ID: 21106982)
1. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
3. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.
Jin L; Tabe Y; Kimura S; Zhou Y; Kuroda J; Asou H; Inaba T; Konopleva M; Andreeff M; Miida T
Br J Cancer; 2011 Jan; 104(1):91-100. PubMed ID: 21139584
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
[TBL] [Abstract][Full Text] [Related]
6. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large b-cell lymphoma.
Mozos A; Roué G; López-Guillermo A; Jares P; Campo E; Colomer D; Martinez A
Am J Pathol; 2011 Nov; 179(5):2601-10. PubMed ID: 21907693
[TBL] [Abstract][Full Text] [Related]
7. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
8. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Weniger MA; Rizzatti EG; Pérez-Galán P; Liu D; Wang Q; Munson PJ; Raghavachari N; White T; Tweito MM; Dunleavy K; Ye Y; Wilson WH; Wiestner A
Clin Cancer Res; 2011 Aug; 17(15):5101-12. PubMed ID: 21712452
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer.
Song D; Chaerkady R; Tan AC; García-García E; Nalli A; Suárez-Gauthier A; López-Ríos F; Zhang XF; Solomon A; Tong J; Read M; Fritz C; Jimeno A; Pandey A; Hidalgo M
Mol Cancer Ther; 2008 Oct; 7(10):3275-84. PubMed ID: 18852131
[TBL] [Abstract][Full Text] [Related]
10. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells.
Sisinni L; Maddalena F; Lettini G; Condelli V; Matassa DS; Esposito F; Landriscina M
Int J Oncol; 2014 Feb; 44(2):573-82. PubMed ID: 24297638
[TBL] [Abstract][Full Text] [Related]
11. PRDM1 is required for mantle cell lymphoma response to bortezomib.
Desai S; Maurin M; Smith MA; Bolick SC; Dessureault S; Tao J; Sotomayor E; Wright KL
Mol Cancer Res; 2010 Jun; 8(6):907-18. PubMed ID: 20530581
[TBL] [Abstract][Full Text] [Related]
12. BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.
Yasui H; Hideshima T; Ikeda H; Jin J; Ocio EM; Kiziltepe T; Okawa Y; Vallet S; Podar K; Ishitsuka K; Richardson PG; Pargellis C; Moss N; Raje N; Anderson KC
Br J Haematol; 2007 Feb; 136(3):414-23. PubMed ID: 17173546
[TBL] [Abstract][Full Text] [Related]
13. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
14. The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.
Georgakis GV; Li Y; Younes A
Br J Haematol; 2006 Oct; 135(1):68-71. PubMed ID: 16925576
[TBL] [Abstract][Full Text] [Related]
15. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase CK2 protects multiple myeloma cells from ER stress-induced apoptosis and from the cytotoxic effect of HSP90 inhibition through regulation of the unfolded protein response.
Manni S; Brancalion A; Tubi LQ; Colpo A; Pavan L; Cabrelle A; Ave E; Zaffino F; Di Maira G; Ruzzene M; Adami F; Zambello R; Pitari MR; Tassone P; Pinna LA; Gurrieri C; Semenzato G; Piazza F
Clin Cancer Res; 2012 Apr; 18(7):1888-900. PubMed ID: 22351691
[TBL] [Abstract][Full Text] [Related]
17. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
[TBL] [Abstract][Full Text] [Related]
19. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
[TBL] [Abstract][Full Text] [Related]
20. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
